Use of Illumina Deep Sequencing Technology To Differentiate Hepatitis C Virus Variants
Open Access
- 1 March 2012
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 50 (3), 857-866
- https://doi.org/10.1128/jcm.05715-11
Abstract
Hepatitis C virus (HCV) is a positive-strand enveloped RNA virus that shows diverse viral populations even in one individual. Though Sanger sequencing has been used to determine viral sequences, deep sequencing technologies are much faster and can perform large-scale sequencing. We demonstrate the successful use of Illumina deep sequencing technology and subsequent analyses to determine the genetic variants and amino acid substitutions in both treatment-naïve (patient 1) and treatment-experienced (patient 7) isolates from HCV-infected patients. As a result, almost the full nucleotide sequence of HCV was detectable for patients 1 and 7. The reads were mapped to the HCV reference sequence. The coverage was 99.8% and the average depth was 69.5× for patient 7, with values of 99.4% (coverage) and 51.1× (average depth) for patient 1. In patient 7, amino acid (aa) 70 in the core region showed arginine, with methionine at aa 91, by Sanger sequencing. Major variants showed the same amino acid sequence, but minor variants were detectable in 18% (6/34 sequences) of sequences, with replacement of methionine by leucine at aa 91. In NS3, 8 amino acid positions showed mixed variants (T72T/I, K213K/R, G237G/S, P264P/S/A, S297S/A, A358A/T, S457S/C, and I615I/M) in patient 7. In patient 1, 3 amino acid positions showed mixed variants (L14L/F/V, S61S/A, and I586T/I). In conclusion, deep sequencing technologies are powerful tools for obtaining more profound insight into the dynamics of variants in the HCV quasispecies in human serum.Keywords
This publication has 46 references indexed in Scilit:
- Integrative genomics viewerNature Biotechnology, 2011
- Tracking the Evolution of Multiple In Vitro Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep SequencingJournal of Virology, 2010
- Characterization of V36C, a Novel Amino Acid Substitution Conferring Hepatitis C Virus (HCV) Resistance to Telaprevir, a Potent Peptidomimetic Inhibitor of HCV ProteaseAntimicrobial Agents and Chemotherapy, 2010
- Sequence Variability in Clinical and Laboratory Isolates of Herpes Simplex Virus 1 Reveals New MutationsJournal of Virology, 2010
- Identification of a Novel Astrovirus (Astrovirus VA1) Associated with an Outbreak of Acute GastroenteritisJournal of Virology, 2009
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)Antimicrobial Agents and Chemotherapy, 2009
- Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479Antimicrobial Agents and Chemotherapy, 2008
- The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Clonal Integration of a Polyomavirus in Human Merkel Cell CarcinomaScience, 2008